Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2024

Primary Completion Date

July 31, 2025

Study Completion Date

August 31, 2025

Conditions
Androgenetic Alopecia
Interventions
COMBINATION_PRODUCT

5 billion exosomes and saline solution microneedling

Participants will receive 5 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.

COMBINATION_PRODUCT

50 billion exosomes and saline solution microneedling

Participants will receive 50 billion WJMSC-exosome topical application on one half of the treatment area and an equivalent volume of saline solution on the contralateral half of the treatment area. Microneedling at a depth of .5mm on the entire treatment area will immediately follow the exosome and saline application. Participants will also receive 4 permanent microdot tattoos on the aforementioned locations.

Trial Locations (1)

11235

Levit Dermatology, Brooklyn

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

ResilielleTM Age ZeroTM Exosomes

UNKNOWN

collaborator

Dorisca Research Consulting, LLC

UNKNOWN

lead

Levit Dermatology

OTHER

NCT06482541 - Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia | Biotech Hunter | Biotech Hunter